SpaceX has just officially unveiled its next-generation @Starlink Router 4. • Faster peak speeds • Weight: 0.9 lbs (0.4 kg) • Connect up to 510 devices • Coverage of up to 3,500 sq ft • First Starlink router with Wi-Fi 7 chipset • Faster client connections • Water-resistant port covers • Dimensions: 1.8" × 8" × 4.5" (46 × 203 × 115 mm) • Two ethernet ports • LED indicator • Factory reset button • Better performance in congested environments, as well as tri-band radios for enhanced mesh performance • 4x4 (2.4 GHz) and 4x5 (5 GHz), MU-MIMO, OFDMA • WPA2 and WPA3 security • Operating Temperature: -22°F to +122°F (-30°C to +50°C) • IP56 rated (water resistant), configured for indoor use Compatibility: • You can connect third-party hardware to Router 4 by removing the port cover and plugging an ethernet cable into a LAN port.

HERE'S WHAT THE 🇺🇸 STOCK MARKET LOOKED LIKE TODAY Up: - Bloom Energy $BE +10.8% - Lumentum $LITE +5.7% - Applied Materials $AMAT +5.2% - Corning $GLW +4.7% - Marvell $MRVL +4.5% - Oracle $ORCL +4.0% - KLA $KLAC +3.9% - Meta $META +3.2% Down: - SLB $SLB -3.1% - United Rentals $URI -2.8% - Texas Pacific Land $TPL -2.8% - Medtronic $MDT -2.7% - Apple $AAPL -2.7% - Illinois Tool Works $ITW -2.4% - T-Mobile $TMUS -2.1% - Walmart $WMT -1.8% Meta recovered about two-thirds of Monday's -4.8%. Apple and Qualcomm fell for a second straight day. Utilities went from lower on Monday to the best sector in the market today.

HERE'S WHAT THE 🇺🇸 STOCK MARKET LOOKED LIKE TODAY Up: - Palo Alto $PANW +4.6% - CrowdStrike $CRWD +2.8% - Intuitive Surgical $ISRG +2.4% - Hilton $HLT +2.0% - Procter & Gamble $PG +1.9% - Philip Morris $PM +1.8% - Nvidia $NVDA +1.7% - Fortinet $FTNT +1.7% Down: - Qualcomm $QCOM -7.2% - Boeing $BA -6.9% - Intel $INTC -5.7% - Meta $META -4.8% - Regeneron $REGN -4.5% - Newmont $NEM -4.4% - Tesla $TSLA -3.9% - AMD $AMD -3.6% Qualcomm gave back all of Friday's +4.0% and then some. Meta fell for a second straight day after Thursday's +4.5%. Cybersecurity went from the worst group in the market on Friday to the best today.

Foreign born population of each country : Jan 2001 Jan 2025 🇦🇹 8.7% 22.5% 🇧🇪 8.4% 20.2% 🇩🇰 4.8% 14.4% 🇫🇷 5.5% 14.0% 🇩🇪 8.9% 20.5% 🇬🇷 6.9% 11.0% 🇮🇸 3.1% 21.8% 🇮🇪 4.0% 23.3% 🇱🇺 37.5% 51.5% 🇳🇱 4.1% 16.8% 🇳🇴 4.1% 18.7% 🇸🇮 2.1% 15.5% 🇪🇸 3.4% 19.3% 🇸🇪 5.3% 20.8% 🇬🇧 4.3% 20.0% Now add children born to foreign parents and the situation looks even worse. We are living through the demographic annihilation of the people of Europe.

$PGR（Progressive） 5.8.1 快照与技术选股归属：现价222.88，市值129.58B，52周区间189.2到239.38，现金及等价物138.0M，短期投资10005.0M，流动性合计10143.0M，季度经营现金流3607.0M为正，跑道不适用（经营现金流为正，不依赖现金消耗），年度财报12/31/2025收入87671.0M，净利润11308.0M，研发无M，资本支出-348.0M，季度财报6/30/2026收入23609.0M，净利润3311.0M，流动比率nan%，毛利率17.18%，营业利润率16.54%（数据来源：个股基本面快照，2026-10-14）；技术选股D组硬条件命中，分数58.55，获利盘93.15%，套牢盘6.85%，90%集中度6.92（数据来源：技术选股，2026-10-14）。 5.8.2 主营业务与产品技术亮点：Progressive是美国车险龙头，主营个人汽车保险、房屋保险与商业保险。核心技术亮点包括直接分销与代理人双渠道，基于驾驶行为的UBI定价技术，理赔数字化与快速结算能力。本条不写数字。 5.8.3 事件促发点：2026-10-14 Progressive发布财报，预期EPS为4.46，涉及季度业绩，量级判断重大，方向待定（数据来源：未来5日财报日历，2026-10-14）。暂无其他已公开促发点。 5.8.4 大行研报与消息汇总：目标价均值无，买入无，持有无，卖出无（数据来源：Nasdaq分析师库，2026-10-14）。Barclays目标价246上调至247，上调0.4%，头部国际大行，距现价16.4%（数据来源：MarketBeat 2026-10-07）；HSBC目标价221下调至216，下调-2.3%，非头部，距现价1.79%（数据来源：MarketBeat 2026-10-07）。消息面：Zacks对PGR发出混合展望（Foreign Policy Journal 2026-10-13）。 5.8.5 关键价位、触发与失效：日线支撑筹码峰206.04距现价8.17%，日线压力20日高223.78距现价0.4%，周线支撑周线MA10为216.7距现价2.77%，周线压力52周高239.38距现价7.4%（数据来源：个股筹码四元组与关键价位，2026-10-14）。触发条件为放量突破20日高223.78，失效条件为跌破筹码峰206.04。资金共振同向项数2项（数据来源：3.1节，2026-10-14）。 5.8.6 情景：牛档239.38（周线压力52周高），基准档223.78（日线压力20日高），熊档206.04（日线支撑筹码峰）。从现价到周线压力空间7.4%。 5.8.7 结论：等触发，1到2周期望幅度至223.78约0.4%，赔率中性，建议观察，最大风险是财报不及预期。第一目标223.78，第二目标239.38。 5.9 $BIIB（Biogen） 5.9.1 快照与技术选股归属：现价228.9，市值33.82B，52周区间138.0到238.24，现金及等价物3008.5M，短期投资807.2M，流动性合计3815.7M，季度经营现金流448.9M为正，跑道不适用（经营现金流为正，不依赖现金消耗），年度财报12/31/2025收入9890.6M，净利润1292.9M，研发1778.6M，资本支出-153.8M，季度财报6/30/2026收入2736.0M，净利润97.5M，流动比率267.9%，毛利率75.69%，营业利润率18.83%（数据来源：个股基本面快照，2026-10-14）；技术选股D组硬条件命中，分数38.68，获利盘97.73%，套牢盘2.27%，90%集中度11.81（数据来源：技术选股，2026-10-14）。 5.9.2 主营业务与产品技术亮点：Biogen是生物技术公司，主营多发性硬化、阿尔茨海默病与神经科学药物。核心技术亮点包括神经科学管线深度，阿尔茨海默病抗体药物，与Eisai等合作伙伴的全球商业化能力。本条不写数字。 5.9.3 事件促发点：2026-10-12 JPMorgan升级至Overweight，目标价210上调至300，涉及评级与目标价，量级判断重大，方向利多（数据来源：MarketBeat 2026-10-12）。暂无其他已公开促发点。 5.9.4 大行研报与消息汇总：目标价均值241.96，区间175.0到300.0，买入17家，持有6家，卖出1家，下期EPS预测12.41（Dec 2026），近4周EPS上修2家下修1家（数据来源：Nasdaq分析师库，2026-10-14）。JPMorgan升级至Overweight，目标价210上调至300，上调42.9%，头部五大，距现价32.91%（数据来源：MarketBeat 2026-10-12）；UBS目标价240上调至270，上调12.5%，头部国际大行，距现价21.7%（数据来源：MarketBeat 2026-10-09）；BMO目标价未披露至220，来源弱，非头部，距现价-5.12%（数据来源：MarketBeat 2026-10-12）。消息面：无。 5.9.5 关键价位、触发与失效：日线支撑筹码峰217.12距现价5.43%，日线压力20日高238.24距现价4.08%，周线支撑周线MA10为221.97距现价3.03%，周线压力52周高238.24距现价4.08%（数据来源：个股筹码四元组与关键价位，2026-10-14）。触发条件为放量突破20日高238.24，失效条件为跌破筹码峰217.12。资金共振同向项数3项（数据来源：3.1节，2026-10-14）。 5.9.6 情景：牛档238.24（周线压力52周高，与日线压力同位），基准档217.12（日线支撑筹码峰），熊档221.97（周线支撑周线MA10）。从现价到周线压力空间4.08%。 5.9.7 结论：可买，1到2周期望幅度至238.24约4.1%，赔率中性偏多，建议半仓，最大风险是神经科学药物竞争加剧。第一目标238.24，第二目标无更高参照，突破后重算。

OECD Forecasts US 2026 Growth Of 2.2% (Vs 2.0% In June), 2.1% In 2027 (Vs 1.8%) - World 2026 Growth Of 2.9% (Vs 2.8% In June), 3.0% In 2027 (Vs 3.1%) - China 2026 Growth Of 4.5% (Unchanged), 4.2% In 2027 (Vs 4.3%) - Euro Area 2026 Growth Of 1.0% (Vs 0.8% In June), 1.0% In 2027 (Vs 1.2%) - Japan 2026 Growth Of 0.8% (Vs 0.6% In June), 0.7% In 2027 (Vs 0.8%) - UK 2026 Growth Of 1.1% (Vs 0.9% In June), 1.0% In 2027 (Vs 1.1%)

HERE'S WHAT THE 🇺🇸 STOCK MARKET LOOKED LIKE THIS WEEK Chips surged: • Qualcomm $QCOM +13.6% • Intel $INTC +13.3% • AMD $AMD +12.7% • Lam Research $LRCX +9.4% • Applied Materials $AMAT +9.1% • Marvell $MRVL +7.2% Meta $META +12.9% on the week of its Connect keynote. Also up: • Amphenol $APH +8.4% • Amgen $AMGN +7.5% • Palantir $PLTR +6.8% • Seagate $STX +6.8% • Microsoft $MSFT +4.5% Financials had 2 of 23 names green: • Blackstone $BX -5.2% • Wells Fargo $WFC -3.7% • PNC $PNC -3.2% • Morgan Stanley $MS -3.1% Also down: • Oracle $ORCL -7.1% • NextEra $NEE -5.5% • Adobe $ADBE -5.4% • Airbnb $ABNB -5.3% • McDonald's $MCD -4.7% Semis have now led the market two weeks in a row since the AI slowdown selloff on September 14. Intel is up more than +30% over that stretch.

CHOOSE YOUR FIGHTER Warren Buffett vs Stanley Druckenmiller Buffett stepped down as Charman of Berkshire Hathaway $BRK.B today. Druckenmiller has never had a losing year in more than 30 years. Here are their full portfolios as of Q2 2026. BERKSHIRE HATHAWAY - Apple $AAPL: 22% - American Express $AXP: 17% - Google $GOOGL: about 12.6% across both share classes - Coca-Cola $KO: 11% - Bank of America $BAC: 9.2% - Chevron $CVX: 4.7% - Occidental $OXY: 4.3% - Chubb $CB: 3.9% - Moody's $MCO: 3.7% - Kraft Heinz $KHC: 2.6% - DaVita $DVA: 2.1% - Delta $DAL: 1.8% - SiriusXM $SIRI: 1.2% - VeriSign $VRSN: 0.8% - Kroger $KR: 0.7% - Liberty Live $LLYVA: about 0.6% across both share classes - Ally $ALLY: 0.4% - Lennar $LEN: 0.4% - New York Times $NYT: 0.4% - Capital One $COF: 0.2% - Louisiana-Pacific $LPX: 0.1% - Nucor $NUE: 0.1% - Macy's $M: 0.1% - NVR $NVR - Jefferies $JEF - D.R. Horton $DHI DUQUESNE FAMILY OFFICE - Natera $NTRA: 17% - Insmed $INSM: about 5.7% in shares and calls - Taiwan Semi $TSM: 5.4% - Brazil ETF $EWZ: about 5.1% in shares and calls - Amazon $AMZN: about 4.6% in shares and calls - STMicro $STM: 4.5% - S&P 500 Equal Weight $RSP: about 3.7% in calls and shares - Fox $FOXA: about 2.8% across both share classes - YPF $REPYY: 2.7% - CDW $CDW: about 2.7% in shares and calls - BBB Foods $TBBB: 2.3% - Google $GOOGL: 2.3% - Seagate blockstack:native: 2.3% - United Airlines $UAL: 2.1% - Sea $SE: 2.0% - NewAmsterdam Pharma $NAMS: 2.0% - Russell 2000 ETF $IWM: 1.9% in calls - Sandisk $SNDK: 1.5% - Revolution Medicines $RVMD: 1.4% - S&P 500 ETF: 1.3% in calls - Bitdeer: 1.2% - CRH: 1.1% - Delta: 1.1% - Tesla $TSLA: 1.0% in calls - Fluor: 1.0% - D.R. Horton: 0.9% - Coupang: 0.9% - AMD: 0.8% - Palo Alto Networks: 0.8% - Cleveland-Cliffs: 0.8% - Hut 8: 0.7% - Caris Life Sciences: 0.6% - Argentina ETF: 0.6% - Woodward: 0.5% - Meta: 0.5% in calls - Nuvation Bio: 0.5% - Protagonist Therapeutics: 0.5% - Roku: 0.5% - Cavco: 0.5% - ADMA Biologics: 0.4% - Hyperliquid Strategies: 0.4% - Rambus: 0.4% - Rhythm Pharmaceuticals: 0.4% - Champion Homes: 0.4% - Daktronics: 0.4% - PureCycle: 0.4% - Southern Copper: 0.4% - Linde: 0.4% - Entegris: 0.4% - Teva: 0.4% - Unity: 0.4% - Aeva: 0.4% - Riot Platforms: 0.4% - Qnity Electronics: 0.4% - Equinix: 0.4% - Lam Research: 0.4% - Definium Therapeutics: 0.3% - Belite Bio: 0.3% - 10x Genomics: 0.3% - Wabtec: 0.3% - Eli Lilly: 0.3% - Xenon Pharmaceuticals: 0.3% - Olema Pharmaceuticals: 0.2% - Repligen: 0.2% - Rocket Companies: 0.2% - Baidu: 0.2% - Arm: 0.2% - Carvana: 0.2% - Reddit: 0.2% - Alcoa: 0.2% - Thermo Fisher: 0.2% - Danaher: 0.2% - F5: 0.2% - Vista Energy: 0.2% - Skeena Resources: 0.2% - JBS: 0.1% - Monte Rosa Therapeutics: 0.1% - Relay Therapeutics: 0.1% - DBV Technologies: 0.1% - CCC Intelligent Solutions: 0.1% - UWM Holdings: 0.1% - Navitas Semiconductor: 0.1% - Solstice Advanced Materials: 0.1% - FTAI Aviation: 0.1% - Beam Therapeutics: 0.1% - Aurora Innovation: 0.1% - IREN: 0.1% - Grupo Financiero Galicia: 0.1% - Wave Life Sciences: under 0.1% Both own Google, Delta and D.R. Horton. Neither owns Nvidia $NVDA.

━━━━━━━━━━━━━ 【US Listed Stocks Implied Catalyst Brief】🔍 ━━━━━━━━━━━━━ 📅 Date: July 22, 2026 (Wednesday) 🌍 Market: US Equities (NYSE + NASDAQ) 【Executive Summary】 Late July brings a dense calendar of macro data and earnings season for US stocks. Three under-the-radar trends to watch this week: ① Small-cap SaaS firms witness coordinated buying by CEOs and directors ($EVCM, Palisade Bio); insiders start accumulating shares after steep valuation compression. ② Bridgewater’s Q2 13F filings reveal a sharp 70% cut to Apple alongside a 62% increase in $AMD holdings, a clear signal of rotation within AI hardware names. ③ Biotech PDUFA season kicks off; $OTLK faces a July 29 FDA decision with an estimated 89% approval probability. I. Major SEC Filing Announcements (Past 1–2 Weeks) ■ $EVCM EverCommerce Inc. (8-K + Form 4, July 8) CEO Eric Remer purchased 75,000 shares at $9.98 ($748,500). Director Richard Peretz bought 100,000 shares ($995,000). Director Eric Rosenthal acquired 60,000 shares ($601,200). The three executives collectively purchased 235,000 shares on the same day for a total of $2.34 million, marking the largest single-day insider purchase in 18 months. The firm recently divested non-core businesses; its stock trades near the 52-week low of $9.45 with a PS ratio of only 1.8x, representing a 40% discount versus the peer median of 3.0x. ■ $BABA Alibaba Group (8-K, Ongoing Share Repurchases) Repurchases executed between July 2–8: 4.16 million shares on July 2 ($49.99 million); 1.47 million shares on July 8 ($19.99 million). Cumulative repurchases since program authorization stand at 31.26 million shares (0.16% of total shares outstanding). Current trailing PE stands at roughly 12x, within its historical low range. ■ $KR Kroger Co. (8-K, July 1) Definitive agreement to acquire Giant Eagle for a total consideration of $1.65 billion ($1.25 billion cash plus assumption of $400 million debt). Giant Eagle generates approximately $9 billion in annual revenue and operates 197 supermarkets plus 11 pharmacies, with geographic footprints highly complementary to Kroger’s existing markets (OH/PA/WV/MD/IN). II. Insider Trading Activity (Form 4, Past 1–2 Weeks) ■ $EVCM EverCommerce — ⭐Strong Signal CEO and two directors made coordinated purchases totaling $2.34 million on July 8 at average prices ranging $9.75–$10.15. Short interest remains elevated at 8.5% of the float, creating potential short squeeze dynamics on upward price moves. A comparable cluster insider purchase worth $1.8 million in December 2024 preceded a 22% share price gain within six weeks. ■ $FLD Fold Holdings — ⭐CEO Accumulation CEO purchased 250,000 shares at $2.60 on July 6 ($650,000), lifting direct holdings by roughly 15%. The stock sits merely 8% above its 52-week low of $2.40. Q2 earnings are scheduled for July 25. Open interest on $3.00 strike call options has risen noticeably in recent sessions. ■ $PALI Palisade Bio — ⭐Serial Director Buying Director Robert Baltera Jr. completed three tranches of purchases between July 1–8 totaling 125,000 shares: $1.98 (30,000), $2.04 (50,000), $1.97 (45,000), for approximately $250,000 total. His shareholding increased by 34%, representing the largest management purchase since January this year. ■ $ANET Arista Networks — ⚠️CEO Disposition CEO Jayshree Ullal sold approximately 477,000 shares across July 9–10 for aggregate proceeds of $89.5 million. While classified as routine selling, the sizable volume warrants monitoring. III. Institutional Position Shifts from 13F Filings (Latest Quarter) ■ Bridgewater Q2: Sharp 70% Cut to AAPL, +62% Stake Increase in AMD Total portfolio market value stood at $19.2 billion (a $600 million quarter-over-quarter decline). The most notable adjustment: substantial reduction in Apple (-70%), paired with a 420,000-share addition to AMD (+62%). Positions in TSM, NVDA, MU, AVGO, MRVL and other AI semiconductor names were retained. Bridgewater is rotating AI exposure away from richly valued large-cap leaders toward second-tier semiconductor stocks. ■ Berkshire Hathaway Q1 (First Post-Warren Buffett 13F) New $2.6 billion position in DAL (Delta Air Lines), marking a return to airline equities. Stake increase in GOOGL elevated it to the seventh-largest holding. New $55 million position in Macy’s. Full liquidation of AMZN and Visa. The new management team demonstrates a tilt toward value recovery and cyclical consumer plays. ■ Composite Signal: Q2 13F data reflects institutional “sell expensive, buy undervalued” positioning — trimming high-valued AI leaders including MSFT/NVDA/AAPL while adding AMD/MU/MRVL and other second-tier semiconductor names. Select institutions have begun tentative repositioning into rate-sensitive cyclicals such as airlines and retail. IV. Analyst Rating Revisions (Past 1–2 Weeks) ■ $XYZ Block — Piper Sandler Two-Tier Upgrade to Overweight Target price raised from $58 to $100 (+72%), driven by projected gross profit growth and margin expansion. Recent underperformance across payments and consumer finance stocks stems from valuation compression rather than EPS deterioration. The firm also assigned Overweight ratings to V/MA/AXP/AFRM/COF. ■ $FIVE Five Below — Bernstein Upgrade to Outperform Target price lifted from $247 to $250. Discount retailers stand to benefit from consumer downgrading trends amid weaker economic conditions. ■ $ADBE Adobe — HSBC upgraded to Buy ($308) on July 2, followed by another firm downgrade to Sell ($240) on July 21. Widening rating divergence reflects unresolved market debate over AI’s impact on creative software. Bulls argue Adobe Firefly unlocks new growth avenues; bears warn of market share erosion from competitors including Canva. ■ $PLTR Palantir — DA Davidson Upgrade to Buy Target price set at $175. Growth accelerates on both government and commercial demand for its AIP AI platform. ■ $SHOP Shopify — Stifel Upgrade to Buy Target price increased from $110 to $150. Consistent profitability improvement for the e-commerce SaaS platform. V. M&A & Corporate Combination Announcements (Past 1–2 Weeks) ■ GSK Acquisition of $NUVL Nuvalent — $10.6 Billion All-Cash Deal GSK closed its acquisition of Nuvalent on July 15 at $124 per share in all cash. Nuvalent develops precision oncology therapies targeting ALK/ROS1 mutations. The transaction featured a substantial acquisition premium, and Nuvalent delisted from Nasdaq. ■ $AA Alcoa Acquisition of South32 Aluminum Assets — Up to $5.6 Billion On July 1, Alcoa announced acquisition of South32’s integrated bauxite, alumina and aluminum smelting assets to solidify its position as the world’s largest aluminum producer. AA pre-market fell 3.6% on announcement amid investor concerns over overpayment, though scale advantages and cost synergies from integration merit follow-up. ■ $KR Kroger Acquisition of Giant Eagle — $1.65 Billion See Section I above. Kroger intends to accelerate Giant Eagle’s growth via data analytics, e-commerce solutions and operational discipline. VI. Share Repurchase Authorizations (Past 1–2 Weeks) ■ $NU Nu Holdings — New $1 Billion Buyback Program Board approved a 12-month $1 billion repurchase program on June 4. The Brazilian digital bank continues generating substantial excess capital while expanding into Mexico, Colombia and the United States. Current market capitalization stands at roughly $53 billion; the buyback represents approximately 1.9% of market value. ■ $NWSA News Corp — Ongoing $1 Billion Repurchase Program Aggregate repurchases reached $364 million as of July 14 (including a $2.72 million tranche on July 14). Approximately $636 million of authorization remains available, equivalent to 3–4% of market cap, signaling constructive capital return momentum. ■ $BABA Alibaba — Daily Buybacks Ranging $5–20 Million Repurchase pace accelerated in July. Cumulative repurchases since program launch total 31.26 million shares. Sustained buybacks at depressed price levels alongside a 12x PE ratio provide meaningful downside support. VII. FDA Biotech Catalysts ■ $OTLK Outlook Therapeutics (PDUFA July 29, 89% Probability) Bevacizumab BLA for wet age-related macular degeneration (Wet AMD). The regulatory decision is due in 9 days. If approved, it will serve as a lower-cost alternative to Lucentis, with an addressable annual market exceeding $8 billion. Current market cap sits near $300 million; regulatory results will dictate near-term price trajectory. ■ $CAPR Capricor Therapeutics (PDUFA August 22, 67% Probability) Deramiocel for Duchenne Muscular Dystrophy (DMD) cardiomyopathy. The candidate holds Orphan Drug, Rare Pediatric Disease and Fast Track designations amid urgent unmet patient needs. The 67% approval probability implies elevated uncertainty, yet substantial upside potential upon clearance. ■ $CELC Celcuity (PDUFA Date Elapsed, July 20) Gedatolisib for second-line HR+/HER2- breast cancer, granted Priority Review, Breakthrough Therapy and Fast Track status with a historical approval probability of ~90%. The PDUFA deadline passed July 20; official regulatory conclusions await confirmation. ■ $SMMT Summit Therapeutics (PDUFA November 14) BLA submission for EGFR-mutant NSCLC post-TKI treatment failure. Approval would fill an unmet clinical niche for EGFR resistance cases. VIII. Retail Social Media Trending Equities (Past 1–2 Weeks) ■ $SNAP Snap Inc. — Reddit Discussion Volume +633% Spiking social sentiment likely tied to Q2 earnings expectations due late July. Fundamentals remain pressured by fierce advertising competition, while the potential TikTok ban remains unresolved. ■ $SPCX SpaceX — Sustained Retail Investor Enthusiasm 677 Reddit mentions with 78.6% bullish sentiment. SpaceX remains the primary accessible space-sector name for retail investors, keeping sentiment elevated. Valuation bubble risks require vigilance. ■ $GME GameStop — Meme Stock Revival 586 Reddit mentions with 152.6% bullish tilt. July rebound correlates with upcoming Q2 earnings and potential transformation catalysts, though no fundamental inflection is confirmed; price action is largely sentiment-driven. ■ $MU Micron Technology — Heated Bull-Bear Debate 714 Reddit mentions with largely neutral sentiment (only 2.3% bullish). Headwinds include Korean semiconductor financing risks, balanced against long-term HBM demand; market direction remains highly contested. ━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 【Ranked Watchlist】Top 5 High-Potential Equities ━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 🥇 #1#: $EVCM EverCommerce Inc. Core Catalysts: Coordinated insider purchases totaling $2.34 million by CEO and two directors on July 8, the largest cluster management acquisition in 18 months. PS ratio of 1.8x versus peer median 3.0x; non-core asset divestitures set the stage for operating margin improvement. Key Metrics: Share price ~$10.5, market cap $1.85 billion, short interest 8.5% (short squeeze potential). Risks: Small-business SaaS spending may contract amid elevated interest rates; stock remains within a downtrend. Positioning Note: Suitable for medium-to-long-term accumulation on dips. Entry zone $9.5–$10, stop-loss $8.5 (10% below 52-week trough). Target range $13–$15 (implying reversion to 2.5x PS). ━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 🥈 #2#: $XYZ Block Inc. Core Catalysts: Piper Sandler two-tier upgrade to Overweight; target lifted from $58 to $100 (+72%). Gross profit expansion driven by Square merchant ecosystem and Cash App dual engines. Valuations across the payments sector have undergone significant compression. Key Metrics: Current share price ~$75, target $100, PE has retreated to reasonable territory. Risks: Rising consumer loan credit losses, volatile bitcoin-derived revenue, ongoing regulatory uncertainty. Positioning Note: Enter $70–$75 zone, stop-loss $62. Upside toward $95–$100 if Q2 earnings (early August) validate margin expansion. ━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 🥉 #3#: $AMD Advanced Micro Devices Core Catalysts: Bridgewater lifted AMD holdings by 62% in Q2. Institutional capital is rotating out of NVDA toward second-tier AI semiconductor names. MI300/MI400 ramp accelerates, building AMD’s nascent data center GPU footprint. Key Metrics: Clear Q2 institutional accumulation signal; AMD holds cost-performance advantages over NVDA within AI inference workloads. Risks: Competitive pressure from NVIDIA Blackwell architecture, sentiment spillover from Korean semiconductor financing strains, persistent weakness in PC end-markets. Positioning Note: Existing holders may maintain positions; new entries await the $160–$165 zone. Accelerated adoption in AI inference represents the primary H2 2026 catalyst. Stop-loss $140. ━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 🏅 #4#: $OTLK Outlook Therapeutics Core Catalysts: July 29 PDUFA decision (9 days away) for Bevacizumab in Wet AMD with an 89% historical approval probability. Approval would create a low-cost alternative to Lucentis within an $8 billion+ annual addressable market. Key Metrics: Current market cap ~$300 million, PDUFA scheduled July 29. Risks: Severe share price downside if FDA issues a Complete Response Letter (CRL); questions over manufacturing capacity and commercialization capabilities; potential need for partnerships or capital raises for launch. Positioning Note: High risk, high reward. Limit allocation to speculative tranches (≤2% of total portfolio). Pre-PDUFA share price rallies are typical. Reduce half of the position ahead of the decision date to lock in gains regardless of outcome. ━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 🏅 #5#: $BABA Alibaba Group Core Catalysts: Trailing PE of only 12x with sustained daily buybacks of $5–20 million. Top-tier institutions including Bridgewater and Appaloosa (David Tepper; BABA as the largest 11.7% portfolio holding) maintain heavy positions. Growth drivers include AI cloud and cross-border e-commerce. Key Metrics: Share price ~$120, PE 12x, daily buyback range $5–20 million. Risks: Uncertain domestic macro backdrop, US–China tech decoupling risks, intensifying competition from Pinduoduo and Douyin E-commerce. Positioning Note: Scale in tranches between $110–$120 for long-term holdings. The combination of 12x PE and active repurchases offers robust downside protection. Stop-loss $95. ━━━━━━━━━━━━━━━━━━━━━━━━━━━━ Follow, share and save. The Wall Street Watch team will continue tracking developments and interpreting quantitative data. Drawing on the WSV Model, we deliver analysis covering equities, gold, bonds (ETFs), sector rotation metrics and individual stock case studies to capture forward positioning opportunities. ⭐️⭐️⭐️ Disclaimer: All content is for informational reference only and shall not constitute investment advice or trading guidance. Information is compiled from public filings and calculated via quantitative machine learning models. No warranty is made regarding the authenticity, completeness or accuracy of data herein. Past performance does not guarantee future returns; case studies do not guarantee profitable outcomes. Investors act at their own risk. All investments carry risk.